POTENTIAL NEW GENETIC AND BIOCHEMICAL MARKERS OF CHRONIC KIDNEY FAILURE

Risultato della ricerca: Other

Abstract

disease (CKD) is an important source of long-term morbidity and mortality. It has been estimated that CKD affects more than 20 million people in the United States. Given that most patients are asymptomatic until the disease has significantly progressed, they remain unaware of the condition. Thus, it is essential to have clinical practice guidelines (BIOMARKERS aimed at early detection, evaluation, diagnosis, and treatment of this condition.
Lingua originaleEnglish
Pagine111-123
Numero di pagine13
Stato di pubblicazionePublished - 2017

Fingerprint

Asymptomatic Diseases
Genetic Markers
Practice Guidelines
Chronic Kidney Failure
Biomarkers
Morbidity
Mortality
Therapeutics

Cita questo

@conference{d3fe843809454d448a99fc942e586eda,
title = "POTENTIAL NEW GENETIC AND BIOCHEMICAL MARKERS OF CHRONIC KIDNEY FAILURE",
abstract = "disease (CKD) is an important source of long-term morbidity and mortality. It has been estimated that CKD affects more than 20 million people in the United States. Given that most patients are asymptomatic until the disease has significantly progressed, they remain unaware of the condition. Thus, it is essential to have clinical practice guidelines (BIOMARKERS aimed at early detection, evaluation, diagnosis, and treatment of this condition.",
author = "Letizia Scola and Manuela Bova and Domenico Lio",
year = "2017",
language = "English",
pages = "111--123",

}

TY - CONF

T1 - POTENTIAL NEW GENETIC AND BIOCHEMICAL MARKERS OF CHRONIC KIDNEY FAILURE

AU - Scola, Letizia

AU - Bova, Manuela

AU - Lio, Domenico

PY - 2017

Y1 - 2017

N2 - disease (CKD) is an important source of long-term morbidity and mortality. It has been estimated that CKD affects more than 20 million people in the United States. Given that most patients are asymptomatic until the disease has significantly progressed, they remain unaware of the condition. Thus, it is essential to have clinical practice guidelines (BIOMARKERS aimed at early detection, evaluation, diagnosis, and treatment of this condition.

AB - disease (CKD) is an important source of long-term morbidity and mortality. It has been estimated that CKD affects more than 20 million people in the United States. Given that most patients are asymptomatic until the disease has significantly progressed, they remain unaware of the condition. Thus, it is essential to have clinical practice guidelines (BIOMARKERS aimed at early detection, evaluation, diagnosis, and treatment of this condition.

UR - http://hdl.handle.net/10447/332341

UR - https://www.unipapress.it

M3 - Other

SP - 111

EP - 123

ER -